Gastrointestinal disease

University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs

Retrieved on: 
Wednesday, April 10, 2024
Colorectal surgery, Cancer, Gastroenterology, Gastrointestinal disease, Hope, Pancreatic cancer, Hematology, UHA, Communication, Partnership, Research, UCBC, Oncology, History, Patient, Physician, Radiation, Genetic counseling, Nursing

University Cancer & Blood Center has been Northeast Georgia’s leading cancer and hematology treatment center for over 40 years.

Key Points: 
  • University Cancer & Blood Center has been Northeast Georgia’s leading cancer and hematology treatment center for over 40 years.
  • University Health Alliance University Health Alliance allows access to comprehensive, world-class healthcare in the greater Athens area.
  • University Health Alliance is brought to you by the trusted team at University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia.
  • University Health Alliance is a division of University Cancer & Blood Center, LLC.

Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ With the Support of Impulsion PME

Retrieved on: 
Thursday, April 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, Impulsion, Pediatrics, Innovation, Parent, Clinical trial, Therapy, Economic development, Growth, Gastrointestinal disease, Hirschsprung's disease, Pharmaceutical industry

Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent.

Key Points: 
  • Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent.
  • With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials.
  • “The financial support from Impulsion PME will first allow the development of an optimal formulation for this curative treatment and to move quickly towards clinical trials,” says Maxime Ranger, President and CEO of Neurenati.
  • Neurenati gratefully thanks CQDM for its support as entité de référence et d’accompagnement during the due diligence process with IQ.

Patient's Story Leads Smart Scan Medical Imaging to Launch Campaign

Retrieved on: 
Monday, April 15, 2024
Patient, SSMI, Magnetic resonance imaging, Hospital, Marketing, Insurance, Hardship, Employment, MRI, Multimedia, Diagnosis, Letter, Gastrointestinal disease, Medical imaging

Fortunately, Mr., Worzalla took the time to do a quick search online and found out about Smart Scan Medical Imaging and their flat rate of $850 for the same MRI.

Key Points: 
  • Fortunately, Mr., Worzalla took the time to do a quick search online and found out about Smart Scan Medical Imaging and their flat rate of $850 for the same MRI.
  • Chief Medical Officer and Co-Founder Smart Scan Medical Imaging.
  • Smart Scan has collaborated with Mid-West Family a Madison-based Advertising and Marketing firm, to produce an educational video and the launch of #BeatBigHealthcare.
  • Smart Scan Medical Imaging operates clinics in Weston, Eau Claire, and Middleton and offers flat transparent rates for high-quality MRIs performed on new state-of-the-art GE MR scanners.

Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey

Retrieved on: 
Tuesday, April 9, 2024
Adverse, Laxative, Gastrointestinal disease, Defecation, Patient, Human, American Journal, Weight loss, Constipation, News, Quality of life, Vibrant consonant, Hope, Invention, FDA

The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.

Key Points: 
  • The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.
  • Disrupting the U.S. $4.6 billion constipation treatment market, Vibrant Gastro’s first-in-class technology offers providers and patients with a new, non-pharmaceutical alternative to address this issue.
  • Patients track the progress of the treatment on their phone with an app to increase compliance, consistency and to monitor results.
  • A study presented at Digestive Disease Week in 2023 found significant symptomatic relief in patients and a substantially improved quality of life.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
Monday, March 18, 2024
Inflammation, Health, Conference, Database, Patient, Serology, Research, Lymphocyte, Gastrointestinal disease, Doctor of Philosophy, CED, First wave, Abstract, Gastroenterology, DDW, Coeliac disease, IEL

BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024, in Washington, D.C.

Key Points: 
  • “The abstracts accepted for presentation at DDW 2024 showcase significant advancements in the field of gastroenterology, particularly in the precision diagnosis and management of celiac disease through the innovative VCIEL scale that our team has developed,” stated James Sapirstein, Chairman and CEO of First Wave BioPharma.
  • Details on the presentations are as follows:
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, Certification, Quarter, Prevalence, Teva Pharmaceuticals, Gastrointestinal disease, Partnership, ACG, Metoclopramide, Patient, Pharmacy, Gastroparesis, Health care, Holocene, Prescription, Orange Book, Marketing, Gastroenterology, Woman, DDW, PBM, Hospital, Pharmaceutical industry

SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments.

Key Points: 
  • Our commercial team’s dedicated efforts yielded a 107% increase in year-over-year revenue,” stated Dave Gonyer, R.Ph., CEO of Evoke Pharma.
  • Research and development expenses totaled approximately $23,000 for the fourth quarter of 2023 compared with $27,000 for the fourth quarter of 2022.
  • For the fourth quarter of 2023 selling, general and administrative (SG&A) expenses were approximately $3.5 million compared with $2.3 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were approximately $3.6 million compared with $2.3 million for the same period of 2022.

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Retrieved on: 
Thursday, March 14, 2024
Conference, Webcast, Patient, Common, Fats, GI, Acquisition, First wave, NIH, Gastrointestinal disease, Series, Marketing, Gastroparesis, FDA, Cystic fibrosis, Food, Digestion, Pharmaceutical industry

BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease. James Sapirstein will continue to serve as Chairman and Chief Executive Officer of First Wave BioPharma with Jack Syage, Ph.D., previously the Chief Executive Officer and Co-Founder of ImmunogenX, assuming the role of President and Chief Operating Officer of First Wave BioPharma. Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.

Key Points: 
  • Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.
  • First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval.
  • First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase.
  • First Wave BioPharma will host a conference call and live audio webcast today, March 14, 2024, at 8:30 a.m.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Retrieved on: 
Wednesday, March 13, 2024
COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.